Roche and the government of Abu Dhabi have set up a new public-private partnership to study spinal muscular atrophy and Duchenne muscular dystrophy (DMD) in the Middle East.

Palisade Bio’s PDE4 inhibitor to treat the inflammatory bowel disease ulcerative colitis appears to be effective in mice, according to new data.

Clinical trial sites for cancer are proliferating, but a lack of investigators with experience in trial recruitment is weighing on their performance, according to a report released May 23 by trial analytics company Phesi.

A month after Evotec first alluded to a “strategic reset” to rebalance the company, the German biotech has revealed the end of its gene therapy aspirations.

Medical app developer Click Therapeutics will increase its digital reach by obtaining assets from the recently defunct Better Therapeutics, which began winding down its operations in March.

A digital pathology collaboration between Microsoft, the University of Washington and Providence health network aims to overcome a few of the obstacles to fully implementing artificial intelligence in the field of cancer diagnostics—and in some cases, through sheer scale.

Labcorp has begun rolling out a new blood test that aims to predict the risk of a pregnant person developing preeclampsia, with screening results available as early as the first trimester.

Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation approach for treating atrial fibrillation, which was submitted for FDA review earlier this year.

The Catalogue of Somatic Mutations in Cancer, or COSMIC, has launched its 100th version, parent institution Wellcome Sanger Institute announced May 21. The latest edition of the precision medicine and research resource contains more than 307,000 new gene variants, bringing its total to more than 24 million.

Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time.